Miyagi Cancer Center

Miyagi 981-1293

0 studies enrolling now · 5 studies all time

What they study most

Adult Solid Tumor, B-Cell Malignancies, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN), Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer

Studies at this site

• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) — Running, not enrolling
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck — Stopped early
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) — Completed